Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 14/20 | 0.49 |
| ▸ | MC3R | P41968 | 6/20 | 0.49 |
| ▸ | MC5R | P33032 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | MC1R | Q01726 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327394 | 1.00 | DPP4 (0.51) | DPP4DPP8DPP9DPP7MC4R | |
| SCHEMBL29327382 | 0.88 | MC4R (0.46) | DPP4DPP8DPP9DPP7MC4R | |
| SCHEMBL14028098 | 0.88 | MC4R (0.46) | DPP4DPP8DPP9DPP7MC4R | |
| SCHEMBL1920691 | 0.82 | PANK3 (0.47) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL15039511 | 0.82 | PANK3 (0.47) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL18481446 | 0.82 | MC4R (0.49) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL12536985 | 0.80 | MC4R (0.47) | DPP4DPP8DPP9DPP7MC4R | |
| SCHEMBL4613397 | 0.80 | MC4R (0.61) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL4601228 | 0.79 | MC4R (0.55) | MC4RMC3RMC5RKCNH2MC1R | |
| SCHEMBL4603259 | 0.78 | MC4R (0.54) | MC4RMC3RMC5RKCNH2MC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-2326638-B9 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-11-13 | — | — | EP | disclosed |
| EP-2326638-B1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| WO-2010015972-A1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1912968-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | DPP4 63/4885DPP8 574/4885DPP9 607/4885 |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | DPP4 261/4885DPP8 1140/4885DPP9 1180/4885 |
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | AQP3, SLC6A7, ABCG2 | DPP4 205/4885DPP8 342/4885DPP9 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.